"use strict";(self.webpackChunkstudyu_docs=self.webpackChunkstudyu_docs||[]).push([[7288],{9990:(e,t,n)=>{n.r(t),n.d(t,{assets:()=>d,contentTitle:()=>o,default:()=>h,frontMatter:()=>a,metadata:()=>r,toc:()=>l});var i=n(5893),s=n(1151);const a={slug:"studyu-fab-study-antidepressant-discontinuation",title:"StudyU's Role in Easing Antidepressant Discontinuation in the FAB-Study"},o=void 0,r={permalink:"/de/blog/studyu-fab-study-antidepressant-discontinuation",source:"@site/blog/2023-10-16-studyu-fab-study-antidepressant-discontinuation.md",title:"StudyU's Role in Easing Antidepressant Discontinuation in the FAB-Study",description:"We are pleased to announce the publication of the first research paper utilizing the StudyU platform",date:"2023-10-16T00:00:00.000Z",formattedDate:"16. Oktober 2023",tags:[],readingTime:3.76,hasTruncateMarker:!1,authors:[],frontMatter:{slug:"studyu-fab-study-antidepressant-discontinuation",title:"StudyU's Role in Easing Antidepressant Discontinuation in the FAB-Study"},unlisted:!1,nextItem:{title:"Introducing StudyU to the German Federal Minister of Health",permalink:"/de/blog/federal-health-minister-meets-studyu"}},d={authorsImageUrls:[]},l=[{value:"Unlocking the Power of N-of-1 Trials with StudyU",id:"unlocking-the-power-of-n-of-1-trials-with-studyu",level:2},{value:"Addressing the Antidepressant Discontinuation Challenge",id:"addressing-the-antidepressant-discontinuation-challenge",level:2},{value:"The FAB-Study: A Closer Look",id:"the-fab-study-a-closer-look",level:2},{value:"How StudyU supported the FAB-Study",id:"how-studyu-supported-the-fab-study",level:2},{value:"Promising Potential",id:"promising-potential",level:2},{value:"Conclusion",id:"conclusion",level:2}];function c(e){const t=Object.assign({p:"p",a:"a",h2:"h2",strong:"strong",blockquote:"blockquote"},(0,s.ah)(),e.components);return(0,i.jsxs)(i.Fragment,{children:[(0,i.jsxs)(t.p,{children:["We are pleased to announce the publication of the first research paper utilizing the StudyU platform\nfor a medical study. The paper ",(0,i.jsx)(t.a,{href:"https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-023-05184-y",children:"Study protocol: combined N-of-1 trials to assess open-label placebo treatment for antidepressant discontinuation symptoms [FAB-study]"}),"\nwas published in cooperation with ",(0,i.jsx)(t.a,{href:"https://www.hsu-hh.de/",children:"Universit\xe4tsklinikum Hamburg-Eppendorf"})," and ",(0,i.jsx)(t.a,{href:"https://www.ukgm.de",children:"Universit\xe4tsklinikum Giessen und Marburg"}),",\nboth of them based in Germany."]}),"\n",(0,i.jsx)(t.p,{children:"Let us have a deeper look into the content of this innovative study and what this achievement means for StudyU."}),"\n",(0,i.jsx)(t.h2,{id:"unlocking-the-power-of-n-of-1-trials-with-studyu",children:"Unlocking the Power of N-of-1 Trials with StudyU"}),"\n",(0,i.jsxs)(t.p,{children:[(0,i.jsx)(t.strong,{children:"StudyU"})," is a novel platform leading the way in the digital transformation of N-of-1 trials, the gold standard for\nassessing personalized treatments. N-of-1 trials compare two interventions for each participant to identify the most\neffective one. Comprising the ",(0,i.jsx)(t.strong,{children:"StudyU Designer"})," for specifying and publishing trials and the ",(0,i.jsx)(t.strong,{children:"StudyU App"})," for\nparticipant engagement, the StudyU platform empowers clinicians and researchers globally to conduct secure digital\nN-of-1 trials. ",(0,i.jsx)(t.strong,{children:"StudyU"})," envisions a future of more accessible and collaborative personalized treatments, available as\na free research tool and a versatile resource for clinical practice."]}),"\n",(0,i.jsx)(t.h2,{id:"addressing-the-antidepressant-discontinuation-challenge",children:"Addressing the Antidepressant Discontinuation Challenge"}),"\n",(0,i.jsxs)(t.p,{children:["Antidepressant discontinuation is a complex issue, with many individuals facing adverse effects and symptoms that hinder\nthe process of stopping medication. This can result in unnecessary, long-term use of antidepressants. The FAB-Study\nacknowledges this challenge and proposes a solution around the concept of N-of-1 trials, which involves individual\npatients using the ",(0,i.jsx)(t.strong,{children:"StudyU App"})," to provide personalized insights into their treatment."]}),"\n",(0,i.jsx)(t.h2,{id:"the-fab-study-a-closer-look",children:"The FAB-Study: A Closer Look"}),"\n",(0,i.jsx)(t.p,{children:"The FAB-Study involves conducting a series of randomized, single-blinded N-of-1 trials. In total, 20 patients with fully\nremitted DSM-V major depressive disorder, who are experiencing moderate to severe discontinuation symptoms after\nstopping antidepressants, participate in the study."}),"\n",(0,i.jsxs)(t.p,{children:["Each N-of-1 trial consists of two cycles, each spanning eight weeks. Within these cycles, patients experience two-week\nalternating periods of open-label placebo (OLP) treatment and no treatment, in a randomized order. Their self-reported\ndiscontinuation symptoms are captured twice daily via our smartphone application, ",(0,i.jsx)(t.strong,{children:"StudyU"}),". Additionally, the study\ntracks their expectations about discontinuation symptoms and mood states."]}),"\n",(0,i.jsxs)(t.p,{children:["More information about the study is available in the open access paper: ",(0,i.jsx)(t.a,{href:"https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-023-05184-y",children:"Study protocol: combined N-of-1 trials to assess open-label placebo treatment for antidepressant discontinuation symptoms [FAB-study]"})]}),"\n",(0,i.jsx)(t.h2,{id:"how-studyu-supported-the-fab-study",children:"How StudyU supported the FAB-Study"}),"\n",(0,i.jsxs)(t.p,{children:["For the successful execution of a digital N-of-1 study, supportive and patient-friendly tools are essential. Due to the\nunique nature of N-of-1 trials and their special requirements, the N-of-trial tailored platform ",(0,i.jsx)(t.strong,{children:"StudyU"})," served as a\nparticularly helpful instrument during the implementation of the FAB-Study:"]}),"\n",(0,i.jsxs)(t.blockquote,{children:["\n",(0,i.jsx)(t.p,{children:'"The new StudyU platform greatly supported the FAB-Study, by serving as an easy-to-use and cost-effective therapeutic\ntool for us. Working with StudyU proved to be a pleasant experience for both the researchers and our patients. We will\ndefinitely consider using StudyU for future N-of-1 studies."'}),"\n",(0,i.jsx)(t.p,{children:"-Amke M\xfcller, study director of the first medical study utilizing StudyU"}),"\n"]}),"\n",(0,i.jsx)(t.h2,{id:"promising-potential",children:"Promising Potential"}),"\n",(0,i.jsx)(t.p,{children:"The results of the FAB-Study may provide valuable insights into the clinical use of open-label placebos for treating\nantidepressant discontinuation symptoms. Furthermore, the study not only addresses the clinical challenge at hand but\nalso investigates the feasibility and applicability of a series of N-of-1 trials in a clinical discontinuation trial.\nSuch insights could pave the way for more personalized, patient-centric treatments."}),"\n",(0,i.jsx)(t.p,{children:"As N-of-1 studies become more widespread, digital N-of-1 platforms could play a vital role in the future in supporting\npersonalized healthcare. They provide the infrastructure needed to streamline the trial process, from specifying\ninterventions to real-time data collection and analysis. In addition, digital N-of-1 platforms play a key role in the\nadoption of N-of-1 studies, as traditional analog methods had limitations in their implementation."}),"\n",(0,i.jsxs)(t.p,{children:["With digital platforms, such as ",(0,i.jsx)(t.strong,{children:"StudyU"}),", trials can be conducted remotely or via smartphones, enhancing participant\nengagement and ensuring the accuracy and integrity of the data. The scalability and efficiency they offer make N-of-1\ntrials more accessible and practical for personalized treatment assessment, holding great promise for the future of\nhealthcare."]}),"\n",(0,i.jsx)(t.h2,{id:"conclusion",children:"Conclusion"}),"\n",(0,i.jsxs)(t.p,{children:["As the developers of the ",(0,i.jsx)(t.strong,{children:"StudyU"})," platform, we are pleased to see ",(0,i.jsx)(t.strong,{children:"StudyU"})," being actively used in health research.\nIt makes us proud to see how ",(0,i.jsx)(t.strong,{children:"StudyU"})," contributes to an important research topic in the field of antidepressant\ndiscontinuation. The FAB study is an example of the potential of personalized medicine and the central role ",(0,i.jsx)(t.strong,{children:"StudyU"}),"\ncan play in this area."]}),"\n",(0,i.jsxs)(t.p,{children:["For us, the paper represents a significant step toward enhancing healthcare and improving the lives of patients. We are\nexcited about the future and the possibilities that personalized healthcare, powered by technologies like ",(0,i.jsx)(t.strong,{children:"StudyU"}),", holds."]})]})}const h=function(e={}){const{wrapper:t}=Object.assign({},(0,s.ah)(),e.components);return t?(0,i.jsx)(t,Object.assign({},e,{children:(0,i.jsx)(c,e)})):c(e)}},1151:(e,t,n)=>{n.d(t,{Zo:()=>r,ah:()=>a});var i=n(7294);const s=i.createContext({});function a(e){const t=i.useContext(s);return i.useMemo((()=>"function"==typeof e?e(t):{...t,...e}),[t,e])}const o={};function r({components:e,children:t,disableParentContext:n}){let r;return r=n?"function"==typeof e?e({}):e||o:a(e),i.createElement(s.Provider,{value:r},t)}}}]);